Lymphotoxin prevention of diethylnitrosamine carcinogenesis in vivo.
Development of intervention measures to control cancer would be facilitated by being able to monitor in vivo carcinogenesis by in vitro quantitation of early indices of neoplastic transformation to assess the in vivo effectiveness of preventive-therapeutic measures. Pregnant Syrian golden hamsters were used in an in vivo-in vitro transplacental model of carcinogenesis to determine the extent that in vivo administration of immunologic hormone preparations along with chemical carcinogen would prevent morphologic transformation assessed in vitro. Pregnant hamsters at 10-11 days of gestation were given injections ip of 3 mg diethylnitrosamine (DENA)/100 g body weight and were killed 2 days later when fetal cells were seeded for colony formation. The frequency of morphologically transformed colonies was assessed after 7 days of growth. Cloning efficiency and mean transformation frequency after DENA exposure were 3.6% and 1 X 10(-4) per cell seeded, respectively. The ip injection of an immunologic hormone preparation reduced the transformation frequency by 46%. The hormone preparation, containing 10,000 U of lymphotoxin but no detectable interferon, was the ultrafiltered lymphokines (greater than 10,000 mol wt) from phytohemagglutinin-stimulated hamster peritoneal leukocytes. The effect of lymphotoxin on cocarcinogenic exposure of fetal cells to DENA in vivo followed by X-irradiation in vitro was also determined. Cells exposed to 250 rad in vitro had a cloning efficiency of 0.5% and a transformation frequency of 0.4 X 10(-4) per cell seeded. After DENA injection and X-irradiation, the transformation frequency increased to 1 X 10(-4) and was inhibited 64% by lymphotoxin in vivo. Thus immunologic hormones (e.g., lymphotoxin) can prevent carcinogenesis in vivo. Furthermore, in vitro quantitation of transformation is a rapid means for evaluating therapeutic and autochthonous effector mechanisms for their ability to prevent or otherwise modulate carcinogenesis in vivo.
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000276:immunology; D006224:Cricetinae; D004052:Diethylnitrosamine / Q000494:pharmacology*; D005260:Female; D008233:Lymphotoxin-alpha / Q000494:pharmacology*; D008431:Maternal-Fetal Exchange; D008647:Mesocricetus; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000209:etiology / Q000276:immunology; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D009602:Nitrosamines / Q000494:pharmacology*; D011247:Pregnancy
D008233:Lymphotoxin-alpha; D009602:Nitrosamines; D004052:Diethylnitrosamine